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Purpose: Relapse after complicated intra-abdominal infection (cIAI) remains common after 25 
treatment. The optimal antibiotic treatment duration for cIAIs is uncertain, especially in cases 26 
where source control is not achieved. We hypothesised that in patients with cIAIs, regardless 27 
of source control intervention, there would be a lower relapse rate with long course antibiotics 28 
(28 days) compared to short course (≤10 days). We piloted a trial comparing ≤10 days to 28 29 
days antibiotics for cIAI.  30 
Methods: A randomised controlled unblinded feasibility trial was conducted. Eligible 31 
participants were adult patients with a cIAI that was diagnosed ≤ 6 days prior to screening. 32 
Randomisation was to long course (28 days) or short course (≤10 days) antibiotic therapy. 33 
Choice of antibiotics was determined by the clinical team. Participants were followed up for 90 34 
days. Primary outcomes were willingness of participants to be randomised and feasibility of 35 
trial procedures. 36 
Results: In total, 172 patients were screened, 84/172 (48.8%) were eligible and 31/84 (36.9%) 37 
were randomised. Patients were assigned to either the short course arm (18/31, 58.0%) or the 38 
long course arm (13/31,41.9%). One patient in the short course arm withdrew after 39 
randomization. In the short course arm, 4/17 (23.5%) were treated for a cIAI relapse vs 0/13 40 
(0.0%) relapses in the long course arm. Protocol violations included deviations from protocol 41 
assigned antibiotic duration and interruptions to antibiotic therapy. 42 
Conclusions: This feasibility study identified opportunities to increase recruitment in a full 43 
trial. This study demonstrates completion of a randomized controlled trial to further evaluate 44 
the optimum antibiotic duration for cIAIs is feasible. 45 
Trial registration: NCT03265834. 46 





Complicated intra-abdominal infections (cIAIs) extend beyond the hollow viscus of origin into 50 
the peritoneal space and are associated with either abscess formation or peritonitis [1]. They 51 
are heterogeneous in aetiology and include spontaneous infections arising from a perforated 52 
intra-abdominal viscus, and post-operative infections. Despite the varied origin of these 53 
infections, there are similar management strategies that centre on source control, e.g. 54 
drainage of intra-abdominal fluid collections, and administration of antibiotic therapy. These 55 
infections are challenging to manage, in part due to the varied pathology that causes them, 56 
and are associated with significant morbidity and mortality [2, 3]. Despite this burden of 57 
disease, there is little clinical evidence on which to base antibiotic treatment. At present there 58 
have been two trials into antibiotic durations for cIAI. The STOP-IT trial [4], which compared 4 59 
vs. 8 days (median durations) found that longer durations significantly reduced the time until 60 
relapse (p=<0.001). The DURAPOP trial compared 8 to 15 days duration and found a lower 61 
rate of clinical failure in patients with the longer course antibiotics, 24% (28/120) with 8 days 62 
and 14% (16/116) with 15 days (p=0.54) [5]. Given that there remains a high relapse rate, it 63 
has been suggested that longer courses of antibiotics may reduce relapse of cIAIs[6]. In the 64 
UK, for serious infections (brain abscess, mastoiditis, septic arthritis, osteomyelitis, lung 65 
abscess, endocarditis, and prostatitis) which have a high risk of relapse and associated 66 
mortality, microbiologists often recommend up to and beyond four weeks of antibiotic therapy. 67 
This approach has not yet been investigated in a RCT for cIAIs. Furthermore, around 30% 68 
of patients in England and Scotland, do not undergo source control procedures [7] and 69 
thus far there have been no trials evaluating antibiotic duration in this patient group. 70 
We therefore hypothesise that in patients with cIAIs, regardless of source control intervention; 71 
there will be a lower relapse rate when treated with 28 days of antibiotics compared to ≤10 72 
days of antibiotics.  73 
Materials and Methods 74 
Trial design: An unblinded parallel group randomised controlled feasibility trial comparing 75 
long course (28 days) to short course (≤10 days) antibiotic therapy in patients with cIAI was 76 
carried out. This feasibility trial was approved by the Yorkshire and Humber (Leeds–East) 77 
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Research Ethics Committee, UK (16/YH0453) (ClinicalTrials.gov Identifier: NCT03265834). 78 
The study is reported according to the CONSORT extension to pilot and feasibility trials, see 79 
supplementary material. 80 
Participants: Participants were eligible if they were aged ≥ 18 years old and had been 81 
diagnosed with a cIAI. The diagnostic criteria for a cIAI diagnosis included the presence of 82 
both radiological and clinical features consistent with a cIAI, including a fever (temperature of 83 
≥38 ˚C) and a neutrophilia (> 7.5 x 10*9/L) or intra-operative confirmation of an abscess. Any 84 
cIAI diagnosed >6 days prior to screening was excluded. Patients were identified either by 85 
notification by a member of the patient’s clinical team to the research team, or by screening of 86 
radiology reports. Participants were excluded if their cIAI was associated with uncomplicated 87 
appendicitis, primary complicated appendicitis,  pancreatitis, pelvic inflammatory disease, 88 
primary (spontaneous) bacterial peritonitis (SBP), continuous ambulatory peritoneal dialysis 89 
peritonitis (CAPD peritonitis) and Clostridium difficile infection as they were consider distinct 90 
conditions with separate management strategies. Patients were recruited from Leeds 91 
Teaching Hospitals NHS trust in the United Kingdom between August 2017 and June 2018. 92 
The trial was stopped at the end of funding for the trial research staff.  93 
Interventions: Participants received either ≤ 10 days (short course [SC]) or 28 days (long 94 
course [LC]) of antibiotic therapy. The clinical team caring for the patient determined the choice 95 
of antibiotic, as the aim was to compare antibiotic prescribing strategies (i.e. short course vs 96 
long course) rather than individual drugs or specified combinations of drugs. The antibiotic 97 
prescribed was chosen according to the available clinical and microbiological data, in 98 
conjunction with local antibiotic guidelines, and altered as new results and clinical 99 
information become available.  100 
Outcomes: The primary outcomes were to determine trial feasibility and included: the 101 
willingness of participants to be randomised, the willingness of clinicians to allow patients to 102 
be recruited, the number of eligible patients and follow up rates. Additionally, data on clinical 103 
objectives that would be the primary and secondary objectives for a definitive study following 104 
on from the feasibility study were collected in order to determine the feasibility of collecting 105 
this information. These clinical objectives included rate of relapse, mortality, total days of 106 
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antibiotic consumption, all infections within 90 days of cIAI diagnosis, length of hospital stay 107 
and number of source control procedures required. Participants were followed up for 90 days 108 
and outcomes assessed at 30 days and 90 days post cIAI diagnosis (via telephone 109 
consultation or inpatient review).  110 
Relapse of cIAI was defined as relapse of infection occruing after surgical and antibiotic 111 
therapy to manage the primary CABI had been considered successful (as demonstrated 112 
by antibiotics being stopped and no further source control procedures planned). 113 
Relapse of cIAI included both definite and probable cases. A definite case was defined 114 
as cIAI relapse with a combination of radiological and clinical features consistent with 115 
CABI including a fluid collection, a temperature of ≥38 degrees and a neutrophilia 116 
(neutrophil count > 7.5 x 10*9/L) or intra-operative confirmation of an abscess. Probable 117 
cIAI relapse included cases where there was either absence of radiological imaging or 118 
radiological features inconsistent with a cIAI, but where no other source of infection 119 
was identified, and the patient was managed for a relapsed cIAI.  120 
Quality of life was assessed with the European Quality of Life–5 Dimensions 3-Level 121 
questionnaire (EQ-5D-3L) and the EQ-5D visual-analogue scale (EQ-5D VAS) at baseline, 122 
day 30, day 90 and at the time of cIAI relapse. 123 
Sample size: Given that this was a feasibility study, no formal sample size calculation was 124 
performed and a maximum patient recruitment target of 60 patients was set [8]. 125 
Randomisation: Patients in each intervention arm were stratified into two groups; post-126 
operative cIAIs (cIAI within 90 days of surgery) and non post-operative cIAIs (primary cIAIs). 127 
Simple randomisation with a 1:1 allocation ratio was then used to allocate patients.  128 
Sequence generation: A web based sequence generator was used to generate an 129 
unpredictable allocation sequence (https://www.random.org/sequences/).  130 
Allocation concealment: An independent person outside of the research team transferred 131 
the sequence into sealed envelopes, which were then accessed after trial enrolment to 132 
allocate participants to a treatment arm. 133 
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Implementation: Patient’s allocation was determined by a trial researcher (SA, RA & RB) 134 
after a patient had given their consent.  135 
Blinding: Patients, researchers and clinicians were not blinded to the treatment allocation. 136 
Statistical methods: Descriptive statistics were used to report outcomes and baseline 137 
characteristics. Continuous data are summarised as medians and interquartile ranges (IQR) 138 
and categorical data were summarised as proportions (percentage). For clinical outcome 139 
analysis, intention to treat analysis was completed. Sub-group analysis of post-operative cIAIs 140 
vs non post-operative cIAIs was also completed.  All analyses were conducted using the 141 
statistical package SPSS (IBM SPSS Statistics for Windows, Version 23.0, IBM Corp). 142 
Protocol amendments: One protocol amendment was made and implemented during the 143 
study and the substantial changes included the following: The exclusion of any patients who 144 
had a cIAI in the previous one year was changed to three months to allow inclusion of more 145 
patients with cIAIs. The definition of cIAI was amended to include patients with fever prior to 146 
admission and patients who have evidence of purulent peritonitis intra-operatively. An 147 
amendment that was approved but not implemented was for the recruitment of patients via 148 
consultee consent.   149 
Results 150 
Participant flow: From August 2017 to June 2018, 172 patients were assessed for eligibility, 151 
84/172 (48.8%) were eligible for enrolment and 31/84 (36.9%) were enrolled and randomised. 152 
Eight-eight patients were ineligible, of whom 42 (47.7%) were being treated for a cIAI but did 153 
not have a fever and a raised neutrophil count and 14 (15.9%) patients were ineligible because 154 
they had had >6 days of antibiotics for their cIAI. Of the 53/84 (63.1%) patients who were 155 
eligible but not enrolled; 32 declined participation (Table 1),13 were either discharged or had 156 
antibiotics discontinued before consent or approach by the research team, two were not 157 
enrolled at the request of the treating surgeon, two died prior to approach and four were not 158 
recruited for other reasons (one patient was non-english speaking, one was breastfeeding, 159 
one was due to undergo major surgery for another indication and one was unabe to be 160 
followed up due to travel outside of the continent). Patients who declined to participate in the 161 
study were more likely to have had a HDU/ICU admission (13.3% of patients who consented 162 
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to participate had a HDU/ICU admission vs 25.0% of patients who declined to participate). 163 
Reasons for declining to participate included a preference for an antibiotic duration (4/32), 164 
feeling too unwell (4/32), concern over adverse events (3/32), but most commonly no reason 165 
was given (20/32). One patient withdrew from the study after randomisation, the remaining 166 
30/31 randomised patients were followed up for the complete study period. Participant flow is 167 
outlined in the Consolidated Standards of Reporting Trials (CONSORT) flow diagram in Figure 168 
1. 169 
Protocol adherence: Participants were deemed to have received allocated treatment if in the 170 
SC arm they received < 10 days (+1) and in the LC arm 28 days (+/- 1). In the SC treatment 171 
arm, 4/17 (24%) patients continued antibiotics for longer than the allocated duration; two 172 
received 14 days and two received 12 days treatment. Whereas, 5/13 (38%) patients in the 173 
LC treatment arm did not receive the allocated treatment duration of antibiotics; one patient 174 
discontinued early at day 20 due to a serious adverse event (SAE) from co-amoxiclav 175 
(deranged liver function tests), three patients had their antibiotics stopped early (days 4, 5 and 176 
15) inadvertently by members of the clinical team who were unaware of treatment allocation 177 
and one patient continued antibiotics for 30 days. 178 
Baseline data: The baseline characteristics of patients enrolled in the study are summarised 179 
in Table 2. Characteristics of patients in each arm of the study were comparable apart from 180 
the number of patients with post-operative cIAIs, which was higher in the short course arm 181 
(59% vs 31%).   182 
Numbers analysed, Outcomes and Estimations 183 
Intention to treat (ITT) analysis: Overall 4/30 (13.3%) patients had either a definite or 184 
probable cIAI relapse, all of whom were randomised to receive short course antibiotics.  185 
Only one patient died during the study, this patient was randomised to receive 28 days of 186 
antibiotics however treatment was stopped early on day four of treatment.  The overall hospital 187 
stay was 8 days (IQR 4.5-11) in patients who had long course antibiotics and 9 days (IQR 4.5-188 
31) in patients who had short course antibiotics. A higher proportion of patients in the SC arm 189 
had other infection diagnoses during the follow up period compared to the LC arm (6/17 190 
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[35.3%] vs 1/13 [7.9%]). Clinical outcomes are shown in Table 3, and characteristics by 191 
presence or absence of relapse are shown in Table 4. 192 
Sub group analysis: In total, 14/30 (46.7%) patients had a post-operative cIAI (cIAI within 90 193 
days of abdominal surgery). Of these, four received long course antibiotics and ten short 194 
course antibiotics. Out of the four patients who had a cIAI relapse, three had post-operative 195 
cIAIs.  196 
Quality of life analysis: In total, 26/30 participants completed EQ-5D-3L and EQ-VAS 197 
questionnaires for all time points.  For the baseline assessments, data on 1/30 EQ-5D-3L and 198 
2/30 EQ-VAS were missing. One patient died before day 30 assessments took place, and 1/29 199 
day 30 EQ-VAS and 1/29 day 90 EQ-VAS were missing. All four patients who had a cIAI 200 
relapse completed a EQ-5D-3L and EQ-VAS questionairres at the time of cIAI relapse. 201 
Source control procedures: Overall, eight patients did not undergo source control 202 
procedures. Six patients in the SC arm did not under go source control: three of these 203 
patients had post-operative cIAIs, two had complicated diverticular disease and one 204 
had perforated peptic ulcer. Two patients in the LC arm did not undergo source control; 205 
both had cIAI due to complicated diverticulitis.  206 
Of the 11/13 patients who had source control in the LC arm, three had percutaneous 207 
drainage and eight had surgical procedures (four had resection with anastomosis or 208 
closures and four had resection with proximal diversion. In the SC arm, 7/17 had 209 
percuteous drainage and 4/17 had surgical source control (one had surgical drainage, 210 
one had closure of perforation with a washout and two had surgical resection with 211 
proximal diversion). 212 
Antibiotic treatment: The median antibiotic treatment duration was 9 days (IQR 7.5 - 11.5) 213 
in the group of patients receiving SC antibiotics and 28 days (IQR 17.5 - 28.0) in the group 214 
receiving LC antibiotics. The most frequently used intravenous antibiotic regimen was 215 
cefuroxime and metronidazole, which was used in 14/30 (46.7%) participants (6 patients in 216 
LC arm and 8 patients in SC). Piperacillin-tazobactam  was the second commonest antibiotic 217 
regimen and used in 7/30 (23.3%) patients (6 patients in the SC and 1 in the LC arm). 218 
Amoxicillin plus clavulanic acid was the most frequently used oral regimen; 13/30 (43.3%) 219 
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patients (6 in the SC arm and 7 in the LC arm). Two patients out of the 13 patients in the SC 220 
arm had interruptions to their antibiotic course (antibiotics stopped and restarted), this led to 221 
one patient receiving antibiotics for longer than the assigned duration. Overall, seven patients 222 
had their initial antibiotic regimen altered due to the presence of resistant organisms; 3/11 223 
(27.2%) in the LC arm and 4/16 (25.0%) in the SC arm. 224 
Harms: One SAE related to the study occurred in a patient allocated to receive LC who 225 
developed deranged liver function tests (LFTs) which normalised after cessation of antibiotics. 226 
Other SAEs that occurred which were unrelated to the study procedures included: small bowel 227 
obstruction secondary to adhesions, stroke, acute kidney injury, episode of uncomplicated 228 
diverticulitis and pulmonary embolus. There were no episodes of Clostridium difficile 229 
infection.  230 
Discussion 231 
The optimal antibiotic treatment strategy for cIAIs remains uncertain especially in cases where 232 
it is not feasible to perform source control. To date there have been two RCTs which have 233 
evaluated antibiotic duration for cIAIs where source control has been achieved. The STOP IT 234 
trial reported that in patients who had adequate source control, short course antibiotic therapy 235 
(median 4 days) was as effective as long course therapy (median 8 days) [4]. The DURAPOP 236 
trial assessed antibiotic duration for intensive care patients and compared eight days to fifteen 237 
days of antibiotic therapy [5]. The primary outcome was antibiotic free days within the 45 days 238 
after source control and results favoured 8 days of treatment (median number of antibiotic-239 
free days 15 [6-20] vs 12 [6-13] days). However in both trials clinical failure was common (15-240 
24%). One reason for relapse of cIAI may be that antibiotic treatment may not have been given 241 
for long enough to eradicate bacteria from, what should be, a sterile intra-abdominal cavity. 242 
Thus, long course antibiotic therapy may reduce the rate of cIAI relapse . 243 
This RCT of short course (≤ 10 days) or long course (28 days) antibiotic therapy for cIAIs was 244 
designed to determine the feasibility of conducting a definitive RCT. An adequate proportion 245 
(36.7%) of eligible patients were enrolled which suggests that it would be feasible to enrol 246 
patients into such a definitive trial. Additionally, with the exception of two cases, clinicians were 247 
willing for patients to be recruited and patients were able to successfully complete follow-up. 248 
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Whilst our recruitment target of 60 patients was not reached, we recruited sufficient patients 249 
to be able to determine trial feasibility.  250 
During the trial there were minimal data missing on primary and secondary outcome 251 
measures, with the exception of EQ-5D questionnaires. However, the rate of missing data was 252 
low, therefore using EQ-5D questionnaires to calculate QALYs for economic evaluation will 253 
still be a feasible in a definitive trial.  Overall, protocol adherence was 70%, in keeping with 254 
other trials that dictate antibiotic duration: protocol adherence was 82% in the 255 
experimental group & 72.7% in the control group in the STOP IT trial, 79% & 82% in the 256 
two arms in the DURAPOP trial [4, 5]. Non adherence was mostly associated with antibiotics 257 
durations being outside accepted ranges, extending these beyond 24 hours would increase 258 
adherence and not detract from the overall treatment allocations.   259 
We identified aspects of the protocol that reduced recruitment. The definition of cIAI used in 260 
this study was more inclusive than recommended definitions as it allowed surgeons to make 261 
a diagnosis of cIAI without operative evidence, thus allowing inclusion of patients who do not 262 
undergo a source control procedure [9]. However, the definition used for cIAI in this trial 263 
excluded 48% of  patients who were treated for cIAI because they did not have both a recorded 264 
fever (≥ 38°C) and a neutrophilia (>7.5 10*9/L).  In a definitive trial, a more pragmatic definition 265 
should be adopted to ensure evidence is gained for a more representative population of 266 
patients treated for cIAI. Additionally, it was noted  other infections e.g. urinary tract or 267 
respiratory tract infection, not including cIAI relapses, were common, and consideration to 268 
these being included within a primary outcome measure in a definitive trial would be needed. 269 
This study was not designed to detect a clinically significant difference in the 270 
secondary outcomes, however we found that relapses predominantly occurred in 271 
patients who had post-operative cIAIs who received short course antibiotics. Thus, 272 
supporting further research into our hypothesis that longer antibiotic durations may 273 
reduce relapse rates. 274 
Complicated intra-abdominal infections continue to be associated with significant morbidity 275 
and mortality. This trial demonstrates the feasibility of a substantive RCT to further investigate 276 
antibiotic durations for the management of cIAIs.  277 
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Table 2. Baseline characteristics of patients in each study arm 




Age (years) 60.0 (46.5-74.5) 63.0 (46.0-72.0) 
Female 5/13 (38.5%) 6/17 (35.3%) 
Charlson score  4 (1.5-8.5) 4 (1-5) 
HDU/ICU Admission 2/13 (15.4%) 2/17 (11.8%) 
Post-operative infection 4/13 (30.8%) 10/17 (58.8%) 
Perforated viscus 7/13 (53.8%) 5/17 (29.4%) 
Presence of a collection 8/13 (61.5%) 14/17 (82.4%) 
Anastomotic leak 1/13 (7.7%) 4/17 (23.5%) 
Site of cIAI     
Appendix 0/13 (0%) 1/17 (5.9%) 
Biliary 1/13 (7.7%) 0/17 (0%) 
Colon 5/13 (38.5%) 7/17 (41.2%) 
Small bowel 3/13 (23.1%) 1/17 (5.9%) 
Other  4/13 (30.8%) 7/17 (41.2%) 
Gastro-oesophageal 0/13 (0%) 1/17 (5.9%) 
Baseline health status°ᶺ  35.0 (20.0-50.0) 30.0 (20.0-40.0) 
NEWS* at diagnosis  3.0 (2.0-4.0) 3.0 (1.5-6.0) 
C-reactive protein (mg/L) at 
diagnosis  
220.0 (88.5-276.0) 218.0 (124.0-
290.0) 
Neutrophil count (10*9/L) at 
diagnosis 
13.0 (9.2-15.2) 12.8 (9.4-19.2) 
Temperature at diagnosis °C) 38.3 (38.2-38.5) 38.3 (37.8-38.7) 
Source control procedure     
Percutaneous drainage  3/13 (23.1%) 7/17 (41.2%) 
Surgical  8/13 (61.5%) 4/17 (23.5%) 
Nil 2 (15.4%) 6/17 (35.3%) 
Samples∞ sent for culture 11/13 (84.6%) 16/17 (94.1%) 
Antibiotic regimen altered 
due to drug resistant bacteria  
3/11 (27.2%) 4/16 (25.0%) 
Data are median (IQR) or n/total (%).  
°Measured by patient self-reported rating (EQ5D-VAS) on own overall health, scale from 0 (worst possible health) to 100 (best 
possible health). *National Early Warning Score. ᶺdata missing in 1/13 in LC arm and 1/17 in SC arm. ∞Samples include blood 





 Consented (n 31)  Declined (n 32) 
Age (years) 61.0 (45.0-72.0) 60.5 (48.3-79.3) 
Females 11/31 (35.5%) 17/32 (53.1%) 
Charlson score 4 (1-5) 4 (1.3-5) 
HDU/ICU Admission 4/31 (12.9%) 8/32 (25.0%) 
Post-operative infection 14/31 (45.2%) 13/32 (40.6%) 
Presence of a perforated viscus 13/31 (41.9%) 13/32 (40.6%) 






























Antibiotic duration (days) for cIAI 11.5 (8.0-28.0) 28 (17.5-28.0) 9 (7.5-11.5) 
Relapse 4/30 (13.3%) 0 (0%) 4/17 (23.3%) 
Death 1/30 (3%) 1/13 (7.7%) 0/17 
Total antibiotic consumption (days)  
within 90 days of cIAI diagnosis 
19 (9.8-28.0) 28 (17.5-30.0) 15 (8.5-26.0) 
Length of stay (days) following cIAI 
diagnosis 
8.5(4.8-17.8) 8.0 (4.5-11.0) 9.0 (4.5-31.0) 
Number of source control procedures 
required for the management of cIAI  
1 (0.8-1) 1 (1-1) 1 (0-1) 
Data are median (IQR) or n/total (%) 
 Relapse (n = 4) No relapse (n = 26) 
Age (years) 65.5 (49.5-83.0) 61.0 (45.8-72.0) 
Female 3/4 (75%) 8/26 (30.8%) 
Median Charlson score (IQR) 4.0 (1.5-8.0) 4.0 (1.0-5.3) 
Post-operative infection 3/4 (75.0%) 11/26 (42.3%) 
Presence of a perforated viscus 1/4 (25%) 11/26 (42.3) 
Presence of a collection(s) 3/4 (75%) 19/26 (73.0%) 
Anastomotic leak 1/4 (25%) 4/26 (15.4%) 
NEWS* at diagnosis  3.0 (0.5-6.8) 3.0 (2.0-5.3) 
Source control procedure   
Percutaneous drainage  1/4 (25%) 7/ 26 (26.9%) 
Surgical  2/4 (50%) 9/26 (34.6%) 
Nil 1/4 (25%) 10/26 (38.5%) 
Site of cIAI   
Appendix 0/4 (0%) 1/26 (3.8%) 
Biliary 0/4 (0%) 1/26 (3.8%) 
Colon 2/4 (50.0%) 10/26 (38.5%) 
Small bowel 1/4 (25%) 3/26 (11.5%) 
Other  1/4 (25%) 10/26 (38.5%) 
Gastro-oesophageal 0/4 (0%) 1/26 (3.8%) 
Antibiotic regimen altered due to 
presence of resistance 
2/4 (50%) 5/26 (19.2%) 



































Figure 1. Participant enrolment, allocation, follow-up and analysis 352 
 353 
 354 
Excluded (n= 141) 
• Not meeting inclusion criteria (n= 88) 
• Declined to participate (n= 32) 
• Clinician request (n=2) 
• Discharged or antibiotics stopped 
before approach/consent (n=13) 
• Other reasons (n=4) 
• Patient died before approach/consent 
(n=2) 
Assessed for eligibility (n= 172) 
Intention to treat analysis (n=17)  
• 3/17 probable relapse & 1/17 definite 
relapse 
• 0/17 died 
Lost to follow-up (n= 1 withdrew) 
Allocated to short course (n= 18) 
• Received allocated intervention (n=14) 
• Did not receive allocated intervention 
(n=4)
o Continued antibiotics > 11 days (n=4) 
 
Allocated to long course (n=13) 
• Received allocated intervention (n=8) 
• Did not receive allocated intervention (n= 5) 
o Stopped due to AE (n=1) 
o Stopped early by clinical team (n=3) 
o Continued antibiotics > 29 days (n=1) 
Intention to treat analysis (n=13)  
• 0/13 relapses 
• 1/13  died 
 




Randomised (n= 31) 
Enrolment 
